Central haemodynamics and plasma prostaglandin E2 in borderline and sustained essential hypertensive patients before and after indomethacin. 1981

M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez

1. In basal conditions, plasma arterial prostaglandin (PG) E2 was significantly increased in borderline hypertensive patients (BH) (28.5 +/- 6.7 pg/ml) in comparison with sustained essential hypertensive patients (EH) (11.6 +/- 3.2 pg/ml) and in comparison with control normotensive subjects (NTS) (5.8 +/- 1.4 pg/ml). 2. Plasma arterial PGE2 was positively significantly correlated with cardiac index and negatively significantly correlated with total peripheral resistance in basal conditions. 3. Indomethacin induced more pronounced haemodynamic changes in borderline than in sustained hypertensive patients, with a significant increase in arterial blood pressure and total peripheral resistance and a significant decrease in stroke volume and cardiac index. 4. Indomethacin significantly decreased arterial PGE2 in borderline hypertensive patients. The decrease was less important in sustained hypertensive patients. 5. In the overall population, a significant positive correlation between arterial PGE2 concentration and cardiac index was observed before and after indomethacin treatment. 6. The study suggests an important role of PGE2 in the regulation of cardiac output (positive inotropic effect) and blood pressure of essential hypertensive patients.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2

Related Publications

M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
April 1986, Nihon Jinzo Gakkai shi,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
January 1980, British journal of clinical pharmacology,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
June 1991, Hypertension (Dallas, Tex. : 1979),
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
July 1999, Oral diseases,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
January 1977, Acta medica Scandinavica. Supplementum,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
January 1990, British journal of clinical pharmacology,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
January 1996, Clinical and experimental obstetrics & gynecology,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
June 1987, Zhonghua xin xue guan bing za zhi,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
April 1983, Acta pharmacologica et toxicologica,
M E Safar, and A F Hornych, and J A Levenson, and A C Simon, and G M London, and J L Bariéty, and P L Milliez
May 1976, Clinical science and molecular medicine,
Copied contents to your clipboard!